Sun, Dec 21, 2014, 3:37 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vringo, Inc. Message Board

edvacourt 13 posts  |  Last Activity: Dec 10, 2014 1:14 PM Member since: Oct 23, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • edvacourt by edvacourt Oct 21, 2014 10:09 AM Flag

    To develop a safer shortcut is perhaps among the biggest things one can announce in scientific exploration. The good news about this is that it is likely just the first in a series of announcements. Many have screamed that HYSR has been too slow but science is painstaking and it can't be rushed. I'd say for a little group like HYSR that is trying to make history they have come a long way in a short period of time. UCSB must be very proud today as well. I look for this to test the highs again in the next couple of months.

    Sentiment: Strong Buy

  • edvacourt by edvacourt Nov 3, 2014 10:07 AM Flag

    One of the things many people have worried about over time is that HYSR seems to operate in a bubble and other than the UCSB deal and some advancement pronouncements basically there isn't much to show for anything. The announcement this morning that the University of Iowa is now engaged as well can only be viewed as an affirmation of the science and perhaps a sign that Hypersolar is moving into the stage where they have a real shot at the 1.5V level. The prior announcement that they had figured out how to separate hydrogen and oxygen gas bubbles in the same reactor we believe is a precursor to an update on the voltage itself. It is quite possible with this new agreement in place that the next announcement we hear will have something to do with voltage level. It also seems appropriate that that would come after today's announcement. As always do your own due diligence.

    Sentiment: Strong Buy

  • Reply to

    Near Term Clinical Progression Goals

    by searleg Nov 20, 2014 11:40 AM
    edvacourt edvacourt Nov 20, 2014 12:41 PM Flag

    I agree with your assessment vvvvv-the Hep C results should really move AEMD. In my view AEMD is extraordinarily undervalued at this moment. Market Cap could have a "b" after it at some point next year. There are too many examples of biotechs that have that kind of value, are pre-revenue and don't seem to have anything like the potential of Aethlon.

    Sentiment: Buy

  • edvacourt by edvacourt Nov 23, 2014 3:56 PM Flag

    Something to consider as we await the Medicity study results. There are some 12 Million cases of Hepatitis C in India currently. If just 2% of that number receive one, three-day, treatment protocol with the Hemopurifier annually, we are talking 240,000 treatments at a known current cost of $7,400 per treatment. That yields approximately $1.7b in treatment revenue. Of course once the Hemopurifier is mass produced costs may be reduced but it's also possible 5-10% of all cases receive treatment. Critically, this is just one of dozens of indications that the Hemopurifier may ultimately be able to treat and in only one country (India) if talking about Hep C's 150M+ cases worldwide. If the upcoming results are as many suspect, hard to imagine that AEMD is not soon valued in the billions. I strongly suspect we are looking at a once in a generation kind of company here.

    Sentiment: Strong Buy

  • Reply to

    AEMD: India Math

    by edvacourt Nov 23, 2014 3:56 PM
    edvacourt edvacourt Nov 23, 2014 8:31 PM Flag

    I get the comment, yes, which is why I used such a modest penetration number. A report by the World Health Organization from 2012 put 25% of India's population having access to healthcare with 50% projected by 2015. As I said, the per treatment cost is likely to come down with mass production but it is likely the percentage treated will go up. Point being that $2b for one indication in one country makes the revenue possibilities both dynamic and dramatic.

    Sentiment: Strong Buy

  • Reply to

    AEMD: India Math

    by edvacourt Nov 23, 2014 3:56 PM
    edvacourt edvacourt Nov 23, 2014 8:40 PM Flag

    Sorry, report was a World Bank report not WHO

    Sentiment: Strong Buy

  • Reply to

    Valuation

    by buckmaker07 Nov 24, 2014 9:50 AM
    edvacourt edvacourt Nov 24, 2014 10:46 AM Flag

    Much more. I know that is difficult to envision for most people but it won't be in 3-6 months time.

    Sentiment: Strong Buy

  • I have written several articles about Aethlon on my blog, edvadailydotcom, and for those wondering what to do rather than watching the tape trying to figure out when to get in or reflexively get out because you are ill informed about the investment and what this company does (or don't know what is directly ahead) you probably need to consider some important points that loom pretty large in the future:

    -35 Hospitals in the U.S. were designated yesterday to treat future Ebola patients. There is a $150M plus earmark in the spending bill, that Congress (in theory) must pass by December 11 to continue funding the government, for these U.S. hospitals to, in part, be outfitted with the best equipment to deal with these patients. Hard to imagine that the Hemopurifier will not be part of that equation and may well be why the company sought to raise what it did so quickly.

    -Kick off of the FDA authorized human trials for HCV patients in the U.S.

    -Update from the company on pathways to commercialization. This is what many are wanting to get a first look at in some broader yet nonetheless comprehensive way. Our assumption is that we will see this in coming weeks.

    These items are just a sampling of the obvious. I have been surprised on several occasions lately in terms of positive items that come up unexpectedly. The Time Magazine recognition stands out and in my view has created the kind of interest in the company where it would be impossible to guess at the number of conversations they are having with interested parties on multiple levels be they potential partners, health organizations or governments. I am by no means telling anyone that they should buy anything but if you are caught looking today you may miss the forest for the trees.

    Lastly, I will be posting an article at some point tomorrow morning which I think many may find interesting. As always do your own due diligence or consult with a trusted financial advisor prior to buying any equity.

    Sentiment: Strong Buy

  • edvacourt edvacourt Dec 3, 2014 1:40 PM Flag

    I don't think there is enough information available about timing and commercialization efforts to offer something that is really fair. I can definitely say that the latest See Thru Equity price target is pretty low. I will detail some of my thinking tomorrow and you should have a better sense.

    Sentiment: Strong Buy

  • This is why you need to have some patience with science. I will have a write-up on this in just a little while. This is earth shattering news and I think people will continue to wake up to its significance in the days and weeks ahead. For the first time we may see major news coverage of HYSR. Of course no one can guarantee that but I see it as likely.

    Sentiment: Strong Buy

  • Reply to

    I Told You This Was Coming

    by edvacourt Dec 9, 2014 10:13 AM
    edvacourt edvacourt Dec 9, 2014 10:55 AM Flag

    Not everyone will sit and wait anymore. Some company will now jump in and help them cross the finish line. They are too close and there are too many benefits available for the company that partners with them.

    Sentiment: Strong Buy

  • Sometime in the next 24 hours I will release an article which will discuss the Ebola funding provisions in the budget that is due to be voted on by Congress tomorrow. I want to let people know that there are numerous public companies that are likely to impacted by this from those offering drugs and other treatments like Hemopurifier therapy to protective wear, thermometers, high powered cleansing solutions, waste disposal and so on. It is important to note that the world often follows the lead of the U.S. government so we are very likely to see more health agencies and governments around the world follow suit. If you do not subscribe to my blog, edvadailydotcom, please do so and when it is released you will be notified.

    Sentiment: Strong Buy

  • edvacourt edvacourt Dec 10, 2014 1:14 PM Flag

    I only go by what has been documented and what seem like theoretical next steps. I do speculate about what should happen given a certain set of facts (or should be among a group of things that should happen), next. My point regarding the Hemopurifier is that it is clearly NOT an unknown entity here. Its safety is pretty well documented and its efficacy sure seems likely (even according to a couple of Emory doctors who are working on what may best be described as a competitive treatment). It is also an adjunct treatment which means it can and should be used in all or almost all of these cases where its proper administration may be assured. Viral load reduction is appropriate for ANYONE who is fighting infectious diseases. Unless someone can convince me this 100% does not work, and published results from a level 4 biohazard lab mean much more to me than those who write with dubious motives, then I will scream from the hilltops for more hospitals that are treating these patients here and abroad to use it as common practice for all these diseases.

    Sentiment: Strong Buy

VRNG
0.571-0.0024(-0.42%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Under Armour, Inc.
NYSEFri, Dec 19, 2014 4:04 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
Hecla Mining Co.
NYSEFri, Dec 19, 2014 4:00 PM EST